Evidence mapPaperPMID 41226792Full record

ArticleInternational journal of molecular sciences2025

Contribution of Cerebellar Glutamatergic and GABAergic Systems in Premotor and Early Stages of Parkinson's Disease.

Clelia Pellicano, Daniela Vecchio, Federico Giove, Lucia Macchiusi, Marco Clemenzi, Claudia Marzi, Mariana Fernandes, Flavia Cirillo, Silvia Maio, Claudio Liguori and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Clelia PellicanoNeuropsychiatry Laboratory, Clinical Neuroscience and Neurorehabilitation Department, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome, Italy.ORCID 0000-0002-3272-1094
Daniela VecchioNeuropsychiatry Laboratory, Clinical Neuroscience and Neurorehabilitation Department, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome, Italy.ORCID 0000-0001-8428-7376
Federico GioveNeuroimaging Laboratory, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome, Italy.
Lucia MacchiusiNeuropsychiatry Laboratory, Clinical Neuroscience and Neurorehabilitation Department, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome, Italy.ORCID 0000-0003-1602-2397
Marco ClemenziNeuroimaging Laboratory, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome, Italy.
Claudia MarziNeuroimaging Laboratory, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome, Italy.
Mariana FernandesDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 4, 00133 Rome, Italy.
Flavia CirilloNeurology Unit, University Hospital of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.
Silvia MaioNeurology Unit, University Hospital of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.
Claudio LiguoriDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 4, 00133 Rome, Italy.
Fabrizio PirasNeuropsychiatry Laboratory, Clinical Neuroscience and Neurorehabilitation Department, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome, Italy.
Federica PirasNeuropsychiatry Laboratory, Clinical Neuroscience and Neurorehabilitation Department, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome, Italy.ORCID 0000-0002-9546-7038

Funding

Italian Ministry of Health PNRR PNRR-MAD-2022-12375706
6 · The paper itself

Abstract

Parkinson's disease (PD) is a multisystem disorder, with early changes extending beyond basal ganglia circuitries and involving non-dopaminergic pathways, including cerebellar networks. Whether cerebellar dysfunction reflects a compensatory mechanism or an intrinsic hallmark of disease progression remains unresolved. In this cross-sectional study, we examined how cerebellar γ-aminobutyric acid (GABA) and glutamate/glutamine (Glx) systems, as well as their excitatory/inhibitory (E/I) balance, are modulated along the disease course. As to ascertain how these mechanisms contribute to motor and non-motor features in the premotor and early stages of PD, 18 individuals with isolated REM sleep behavior disorder (iRBD), 20 de novo, drug-naïve PD (dnPD), and 18 matched healthy controls underwent clinical, cognitive, and neuropsychiatric assessments alongside cerebellar magnetic resonance spectroscopy (MRS, MEGA-PRESS, 3T). While cerebellar neurotransmitter levels did not differ significantly across groups, dnPD patients exhibited a shift toward hyperexcitability in the E/I ratio, without correlation to clinical or cognitive measures. In contrast, in iRBD, an inverse relationship between heightened GABAergic activity and neuropsychiatric symptoms emerged. These findings suggest an early, dynamic cerebellar involvement, potentially reflecting compensatory modulation of altered basal ganglia output. Our results support cerebellar GABA MRS as a promising biomarker and open perspectives for targeting non-dopaminergic pathways in PD.

Indexed as

Cerebellumgamma-Aminobutyric AcidGlutamic AcidParkinson DiseaseAgedCase-Control StudiesCross-Sectional StudiesFemaleGlutamineHumansMagnetic Resonance SpectroscopyMaleMiddle AgedREM Sleep Behavior Disordergamma-Aminobutyric AcidGlutamic AcidGlutamineglutamate/glutamine (Glx) systemisolated or idiopathic REM sleep behaviour disordermagnetic resonance spectroscopyneuropsychiatric symptomsneuropsychological performanceParkinson’s diseaseγ-aminobutyric acid (GABA)

Identifiers

PMID41226792
PMCPMC12611073

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.